✦ LIBER ✦

A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma

✍ Scribed by Justin Lee; David Hodgson; Edward Chow; Andrea Bezjak; Pamela Catton; Debbie Tsuji; Mary O'Brien; Cyril Danjoux; Charles Hayter; Padraig Warde; Mary K. Gospodarowicz

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 91 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21410

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of bryostatin-1 for pat

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

✍ Lance Pagliaro; Danai Daliani; Robert Amato; Shi-Ming Tu; Donnah Jones; Terry Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

Granulocyte-macrophage-colony stimulatin

Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma : A phase II trial

✍ Brian I. Rini; Walter M. Stadler; Ricardo T. Spielberger; Mark J. Ratain; Nichol 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Due to lack of success with standard chemotherapy and only modest

Phase II study of lenalidomide in patien

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

✍ Toni K. Choueiri; Robert Dreicer; Brian I. Rini; Paul Elson; Jorge A. Garcia; Sn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

Vinblastine and estramustine phosphate i

Vinblastine and estramustine phosphate in metastatic renal cell carcinoma : A phase II trial of the Fox Chase Network

✍ Naomi B. Haas; Bruce J. Giantonio; Samuel Litwin; Carl J. Minniti Jr.; Stephen F 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract ## BACKGROUND It is well known that metastatic renal cell carcinoma (RCC) exhibits constitutive resistance to chemotherapeutic agents. Antimicrotubule agents such as vinblastine are associated with low but reproducible response rates (approximately 12%) in patients with RCC. Estramusti

A phase II study of constant-infusion fl

A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma

✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub

Phase 2 trial of talactoferrin in previo

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma

✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc